Diabetes Drug R&D Services ace

Inquiry

* First Name
* Last Name
* Business Email
Phone
Company/Institution
Job Title
* Services or Products of Interest Visfatin-Targeted Drug Development for Diabetes
When do you expect your project to start?
Project Description
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

Visfatin-Targeted Drug Development for Diabetes

Visfatin has been reported to lower blood glucose by activating insulin receptor signaling in adipocytes and hepatocytes, positioning it as a novel antidiabetic target. Ace Therapeutics specializes in antidiabetic drug development services targeting visfatin, providing integrated solutions from target validation to preclinical efficacy assessment. Our advanced platform incorporates core technologies such as molecular docking, structural optimization, and biomarker analysis, empowering clients to accelerate the development of innovative therapies for type 2 diabetes and its complications.

Visfatin as a Promising Antidiabetic Drug Target

Visfatin, a multifunctional protein also known as nicotinamide phosphoribosyl-transferase (NAMPT), is expressed in various tissues and organs, with predominant expression in visceral adipose tissue. Originally identified as pre-B cell colony-enhancing factor (PBEF), this adipokine exhibits insulin-mimetic properties by enhancing insulin sensitivity, suggesting its potential role in diabetes pathogenesis and therapeutic development. It has been shown that the serum visfatin concentrations are increased along-with the worsening of T2DM which creates a relation between visfatin and T2DM. Recent studies showed that visfatin attaches to the insulin receptor at a location other than that of insulin which shows that it has the insulin-mimetic action and enhances cell proliferation. Thus, visfatin becomes a possible target for diabetes therapy.

Visfatin's function in maintaining blood glucose balance. Fig. 1 Role of visfatin in glucose homeostasis. (Dhankhar, S.; et al., 2023)

Antidiabetic Drug Development Services Targeting Visfatin at Ace Therapeutics

Ace Therapeutics offers end-to-end visfatin-targeted drug development services, spanning from early discovery to preclinical research, with a focus on developing next-generation therapeutics for diabetes and its complications.

Visfatin Target Validation and Mechanism Study

We employ CRISPR-Cas9 genome editing technology to establish visfatin knockout/overexpression cellular and animal models.
Visfatin regulation of key signaling pathways in glucolipid metabolism resolved by proteomics and metabolomics technologies.
Establishment of a visfatin activity detection platform, incorporating enzymatic activity assays and cellular-level functional analyses.

Preclinical Screening and Optimization Services

Lead compound discovery based on AI virtual screening and molecular docking techniques.
Structural biology-guided rational drug design for targeting visfatin.
ADMET property optimization (including permeability, metabolic stability and hERG safety assessment).
Development of dual-target drugs (e.g., Visfatin/GLP-1 receptor co-modulators).

Preclinical Efficacy and Safety Assessment Services

Evaluation of multiple animal models of diabetes

db/db mouse model (glycemic control and islet function evaluation).
High-fat diet-induced insulin resistance model.

Evaluation of diabetic complication therapeutics

Diabetic nephropathy (UACR, glomerulosclerosis score)
Diabetic neuropathy (nerve conduction velocity measurement)

Preclinical safety assessment

28-day repeat dosing toxicity test
Cardiovascular safety (hERG, telemetry ECG)
Genotoxicity and reproductive toxicity assessment

Advantages of Our Visfatin-Targeted Antidiabetic Drug Development Services

Rapid identification of highly active and selective lead compounds using virtual screening and molecular docking technology.
Machine learning-based ADMET predictive modeling to reduce late-stage development risk.
Customized diabetes model to accelerate clients' antidiabetic drug development process.

Ace Therapeutics is committed to applying our expertise to support the development of innovative visfatin-targeted drugs. Please feel free to contact us for more details.

Reference

Dhankhar, S.; et al. Novel targets for potential therapeutic use in Diabetes mellitus. Diabetology & Metabolic Syndrome. 15.1 (2023): 17.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services